Three steps to breaking immune tolerance to Lymphoma: A microparticle approach

Cancer Immunology Research

Volumn 3, Issue 4, 2015, Pages 389-398

  Makkouk, Amani ^a   Joshi, Vijaya B ^b   Lemke, Caitlin D ^a   Wongrakpanich, Amaraporn ^b   Olivier, Alicia K ^c   Blackwell, Sue E ^a   Salem, Aliasger K ^a,b   Weiner, George J ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC; CD134 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGICAL ADJUVANT; MICROSPHERE; TNFRSF4 PROTEIN, MOUSE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; INTERNALIZATION; LONG TERM SURVIVAL; LYMPHOMA CELL; MOUSE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL DEATH; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; SOLUBILITY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSPHERES; NEOPLASM TRANSPLANTATION; PHAGOCYTOSIS; RECEPTORS, OX40; SOLUBILITY;

EID: 84962258492     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0173     Document Type: Article

References (39)

1. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comesofage. J Clin Oncol 2011;29:4828-36.
2. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9.
3. Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ. Intratumoral immunotherapy: using the tumour against itself. Immunology 2005;114: 11-22.
4. Visani G, Isidori A. Doxorubicin variants for hematological malignancies. Nanomedicine 2011;6:303-6.
5. Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012;1:179-88.
6. Locher C, Conforti R, Aymeric L, Ma Y, Yamazaki T, Rusakiewicz S, et al. Desirable cell death during anticancer chemotherapy. Ann New York Acad Sci 2010;1209:99-108.
7. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61.
8. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012;1:894-907.
9. Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, et al. Trial Watch: immunostimulatory cytokines. Oncoimmunology 2012;1: 493-506.
10. Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance? Cancer J 2010;16:311-7.
11. Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. JCell Biochem 2011;112:1969-77.
12. Hollander N. Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol 2012;3:3.
13. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009;113:3546-52.
14. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immunity 2013;13:5.
15. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
16. Conde-Estevez D, Mateu-de Antonio J. Treatment of anthracycline extravasations using dexrazoxane. Clin Transl Oncol 2014;16:11-7.
17. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012;161:505-22.
18. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009;114:3431-8.
19. Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 2009;106:870-5.
20. Tosato G, Cohen JI. Generation of Epstein-Barr virus (EBV)-immortalized B cell lines. Curr Protoc Immunol 2007;Chapter 7:Unit 7.22.
21. Jahrsdorfer B, Blackwell SE, Wooldridge JE, Huang J, Andreski MW, Jacobus LS, et al. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 2006;108:2712-9.
22. Garti N, Benichou A. Double emulsions for controlled-release applications: progress and trends. In: Sjoblom J, editor. Encyclopedic handbook of emulsion technology. New York: Marcel Dekker; 2001, p. 77-408.
23. Chakravarthi SS, De S, Miller DW, Robinson DH. Comparison of antitumor efficacy of paclitaxel delivered in nano- and microparticles. Int J Pharm 2010;383:37-44.
24. Yoo HS, Lee KH, Oh JE, Park TG. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release 2000;68:419-31.
25. Hempel G, Flege S, Wurthwein G, Boos J. Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2002;49:133-41.
26. Makkouk A, Joshi VB, Wongrakpanich A, Lemke CD, Gross BP, Salem AK, et al. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer. AAPS J 2015;17:184-93.
27. Committee ACPRW Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, et al. AACR cancer progress report 2013. Clin Cancer Res 2013;19(20 Suppl):S4-98.
28. Silva JM, Videira M, Gaspar R, Preat V, Florindo HF. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release 2013;168:179-99.
29. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Exp Rev Vaccines 2010;9:1095-107.
30. Sheng Sow H, Mattarollo SR. Combining low-dose or metronomic chemotherapy with anticancer vaccines: a therapeutic opportunity for lymphomas. Oncoimmunology 2013;2:e27058.
31. Shurin GV, Tourkova IL, Shurin MR. Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells. J Immunother 2008; 31:491-9.
32. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202:1691-701.
33. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009;15:1170-8.
34. Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Science gone translational: the OX40 agonist story. Immunol Rev 2011; 244:218-31.
35. Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res 2014;2:142-53.
36. Timar J, Ladanyi A, Forster-Horvath C, Lukits J, Dome B, Remenar E, et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial. J Clin Oncol 2005;23:3421-32.
37. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010;28:4324-32.
38. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010;33:225-35.
39. Demento SL, Cui W, Criscione JM, Stern E, Tulipan J, Kaech SM, et al. Role of sustained antigen release from nanoparticle vaccinesinshaping the Tcell memory phenotype. Biomaterials 2012;33:4957-64.